Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
O-Benzylguanine and Temozolomide in Recurrent Glioblastoma
NCT00436436Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2006
- Primary completion
- Mar 2010
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of 6-benzylguanine in glioblastoma multiforme (GBM), sponsored by National Cancer Institute. Started Nov 2006; status: terminated.
02
Drugs
6-benzylguanine
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00436436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00436436.